2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gastrointestinal
1
Conditions
Venous Thromboembolism
22
Neoplasms
15
Pulmonary Embolism
10
Venous Thrombosis
9
Thrombosis
6
Multiple Myeloma
4
Upper Extremity Deep Vein Thrombosis
2
Pancreatic Neoplasms
2
Neoplasm Metastasis
2
Myeloproliferative Disorders
2
Lymphoma
2
Intracranial Thrombosis
2
Hematologic Neoplasms
2
Carcinoma, Hepatocellular
2
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thromboprophylaxis
1
Thromboembolism
1
Thrombocytopenia
1
Thrombocythemia, Essential
1
Stomach Neoplasms
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Polycythemia Vera
1
Ovarian Neoplasms
1
Neoplasms, Plasma Cell
1
Mesenteric Ischemia
1
Leukemia
1
Head and Neck Neoplasms
1
Interventions
Gemcitabine
113
Cisplatin
77
Oxaliplatin
46
pembrolizumab
35
Fluorouracil
33
Capecitabine
31
durvalumab
27
Leucovorin
27
lenvatinib
26
Magnetic Resonance Spectroscopy
15
Irinotecan
14
Drug Therapy
13
Biopsy
13
Nivolumab
12
Albumin-Bound Paclitaxel
12
tislelizumab
11
Specimen Handling
11
Radiofrequency Ablation
11
130-nm albumin-bound paclitaxel
11
pemigatinib
10
apatinib
10
Taxes
10
Radiotherapy
10
Floxuridine
10
Folfox protocol
9
Bevacizumab
9
S 1 (combination)
8
Platinum
8
Photochemotherapy
8
Liver Transplantation
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Cholangiocarcinoma
×
apixaban
×
Clear all
NCT03139487
2020-01-06
PRIORITY
Asan Medical Center
Phase 2
Unknown
176 enrolled